Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cochlear implants cases in Arizona: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 23% on average (17 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 6 | 116 | 44% |
| 2020 | 4 | 96 | 46% |
| 2021 | 5 | 117 | 49% |
| 2022 | 6 | 141 | 51% |
| 2023 | 6 | 168 | 53% |
| 2024 | 8 | 188 | 54% |
| 2025 from claims | – | 143 116–168 | 55% |
| 2026 forecast | – | 154 121–193 | 55% |
| 2027 forecast | – | 164 122–217 | 56% |
| 2028 forecast | – | 175 124–242 | 56% |
| 2029 forecast | – | 187 127–269 | 57% |
| 2030 forecast | – | 200 131–297 | 57% |
Cochlear implantation, children and adults. Professional codes (what the surgeon bills): CPT 69930.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Arizona; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% hospital outpatient. The share outside the hospital has moved −21 pts since 2022.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 14 | 436+11%/yr | +11%/yr | 0.1 | 28% | 770 in 2030+9.8%/yr |
| Colorado | 4 | 157+3.7%/yr | +3.7%/yr | 0.3 | 0% | 110 in 2030−5.3%/yr |
| Washington | 3 | 144+3.9%/yr | +3.9%/yr | 0.2 | 33% | 320 in 2030+14%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Sinus surgery & balloon dilation | 46 | 6,368+5.8%/yr | +5.8%/yr | 8.72.1× | 93% | 7,720 in 2030+3.3%/yr |
| Sleep apnea & airway implants | 8 | 239+57%/yr | +57%/yr | 0.32.3× | 9% | 180 in 2030−4.4%/yr |
| Ear tubes & middle ear surgery | 1 | 177−6.4%/yr | −6.4%/yr | 0.21.2× | 100% | 150 in 2030−2.6%/yr |
Cochlear implants in every state, and its device makers · Every procedure market in Arizona · Every state · Compare with California
Cochlear leads with 72% of company spending on these surgeons in 2025, +45 pts on 2024.
In 2025, 6 companies reported engagement with Arizona’s surgeons worth $28K in consulting, speaking, meals and travel tied to these products, about $3,450 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 15 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.